Changes in RPS14 expression levels during lenalidomide treatment in Low- and Intermediate-1-risk myelodysplastic syndromes with chromosome 5q deletion

Esther N. Oliva, Maria Cuzzola, Francesco Nobile, Francesca Ronco, Maria Grazia D'Errigo, Carmelo Laganà, Fortunato Morabito, Sara Galimberti, Agostino Cortelezzi, Maria A. Aloe Spiriti, Giorgina Specchia, Antonella Poloni, Massimo Breccia, Riccardo Ghio, Carlo Finelli, Pasquale Iacopino, Giuliana Alimena, Roberto Latagliata

Research output: Contribution to journalArticlepeer-review

Abstract

Background: Haploinsufficiency of the ribosomal protein S14 RPS14 gene, located in the common deleted region of chromosome 5q, is a potential causal factor of 5q- syndrome. Lenalidomide elicits high response rates and morphological improvements in myelodysplastic syndrome (MDS) patients with chromosome 5q deletion [del(5q)]. Methods: To further evaluate the role of RPS14, its transcription was tested in bone marrow cells from 17 patients with International Prognostic Scoring System defined Low- or Intermediate-1-risk MDS with del(5q) as a single or additional cytogenetic abnormality receiving treatment with lenalidomide. Results: After 12 wk of lenalidomide treatment, erythroid responses were observed in all cases with an increase in hemoglobin levels of 2.7 ± 2.5 gdL (up to a mean 11.8 ± 1.9 gdL; P = 0.001). Before treatment, RPS14 expression levels were under-expressed in 15 patients with respect to normal controls. After 12 wk of lenalidomide treatment, all patients had an erythroid response. There was a significant increase in median RPS14 expression from baseline 0.01 (IQR 0.05-0.31) to 12 wk 204.71-fold (2.86-446.32; P <0.0001). Conclusions: These observations in the patient setting support the importance of RPS14 in the pathogenesis of MDS with del(5q).

Original languageEnglish
Pages (from-to)231-235
Number of pages5
JournalEuropean Journal of Haematology
Volume85
Issue number3
DOIs
Publication statusPublished - Sep 2010

Keywords

  • del(5Q)
  • lenalidomide
  • myelodysplastic syndromes
  • RPS14

ASJC Scopus subject areas

  • Hematology
  • Medicine(all)

Fingerprint Dive into the research topics of 'Changes in RPS14 expression levels during lenalidomide treatment in Low- and Intermediate-1-risk myelodysplastic syndromes with chromosome 5q deletion'. Together they form a unique fingerprint.

Cite this